Xiu-Xian Wu1, Yoshiyuki Kakehi. 1. Authors' Affiliations: Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan; and Qiqiha Medical College, Heilongjiang, China.
Abstract
PURPOSE: This study was designed to evaluate the apoptotic effect of mapatumumab or lexatumumab, human agonistic antibodies that target the tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2), in combination with chemotherapeutic agents, against human solid cancer cells. EXPERIMENTAL DESIGN: Cytotoxicity was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Synergy was assessed by isobolographic analysis. RESULTS: Treatment of ACHN human renal cell carcinoma cells with cisplatin combined with mapatumumab did not overcome resistance to these agents. However, treatment with cisplatin in combination with lexatumumab had a synergistic cytotoxicity. Synergy was also achieved in six primary renal cell carcinoma cell cultures. Lexatumumab and cisplatin also synergistically enhanced apoptosis. Pretreatment with cisplatin followed by lexatumumab resulted in high cytotoxicity compared with the reverse sequence. Cisplatin significantly increased TRAIL-R2 expression at both the mRNA and the protein levels. Furthermore, the combination of lexatumumab and cisplatin significantly enhanced caspase-8 activity, Bid cleavage, up-regulation of Bax, cytochrome c release, and caspase-9, caspase-6, and caspase-3 activities. Importantly, the activation of caspase-8 was significantly abrogated by the specific inhibitors of caspase-9, caspase-6, and caspase-3. Furthermore, combination-induced cytotoxicity was significantly suppressed by the DR5:Fc chimeric protein and the specific inhibitors of caspase-8, caspase-9, caspase-6, and caspase-3. A similar effect was observed in prostate cancer, bladder cancer, lung cancer, and cervical cancer cells. CONCLUSIONS: Cisplatin sensitizes solid cancer cells to lexatumumab-induced apoptosis by potentiation of the extrinsic and intrinsic apoptotic pathways that lead to amplification of caspase activation, particularly caspase-8, suggesting the combination treatment of solid cancers with cisplatin and lexatumumab might overcome their resistance.
PURPOSE: This study was designed to evaluate the apoptotic effect of mapatumumab or lexatumumab, human agonistic antibodies that target the tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2), in combination with chemotherapeutic agents, against human solid cancer cells. EXPERIMENTAL DESIGN:Cytotoxicity was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Synergy was assessed by isobolographic analysis. RESULTS: Treatment of ACHN humanrenal cell carcinoma cells with cisplatin combined with mapatumumab did not overcome resistance to these agents. However, treatment with cisplatin in combination with lexatumumab had a synergistic cytotoxicity. Synergy was also achieved in six primary renal cell carcinoma cell cultures. Lexatumumab and cisplatin also synergistically enhanced apoptosis. Pretreatment with cisplatin followed by lexatumumab resulted in high cytotoxicity compared with the reverse sequence. Cisplatin significantly increased TRAIL-R2 expression at both the mRNA and the protein levels. Furthermore, the combination of lexatumumab and cisplatin significantly enhanced caspase-8 activity, Bid cleavage, up-regulation of Bax, cytochrome c release, and caspase-9, caspase-6, and caspase-3 activities. Importantly, the activation of caspase-8 was significantly abrogated by the specific inhibitors of caspase-9, caspase-6, and caspase-3. Furthermore, combination-induced cytotoxicity was significantly suppressed by the DR5:Fc chimeric protein and the specific inhibitors of caspase-8, caspase-9, caspase-6, and caspase-3. A similar effect was observed in prostate cancer, bladder cancer, lung cancer, and cervical cancer cells. CONCLUSIONS:Cisplatin sensitizes solid cancer cells to lexatumumab-induced apoptosis by potentiation of the extrinsic and intrinsic apoptotic pathways that lead to amplification of caspase activation, particularly caspase-8, suggesting the combination treatment of solid cancers with cisplatin and lexatumumab might overcome their resistance.
Authors: Suizhao Wang; Wenhong Ren; Jeffery Liu; Guy Lahat; Keila Torres; Gonzalo Lopez; Alexander J Lazar; Andrea Hayes-Jordan; Kebin Liu; Jim Bankson; John D Hazle; Dina Lev Journal: Clin Cancer Res Date: 2010-04-20 Impact factor: 12.531
Authors: A A Farooqi; S Mukhtar; A M Riaz; S Waseem; S Minhaj; B A Dilawar; B A Malik; A Nawaz; S Bhatti Journal: Cell Prolif Date: 2011-10-04 Impact factor: 6.831
Authors: Myoung Woo Lee; Dae Seong Kim; Ji Eun Eom; Ji Won Lee; Ki Woong Sung; Hong Hoe Koo; Young Bin Hong; Keon Hee Yoo Journal: Am J Cancer Res Date: 2022-07-15 Impact factor: 5.942
Authors: V Gunda; O Bucur; J Varnau; P Vanden Borre; M J Bernasconi; R Khosravi-Far; S Parangi Journal: Cell Death Dis Date: 2014-03-06 Impact factor: 8.469
Authors: Q Wang; Q Chen; L Zhu; M Chen; W Xu; S Panday; Z Wang; A Li; O D Røe; R Chen; S Wang; R Zhang; J Zhou Journal: Oncogenesis Date: 2017-07-03 Impact factor: 7.485